Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4543
Title: Second primary cancers in people who had cancer as children: an Australian Childhood Cancer Registry population-based study
Authors: Valery, P. C.
Youlden, D. R.
Baade, P. D.
Green, A. C.
Aitken, J. F.
Moore, Andrew 
Issue Date: 2020
Source: 212, (3), 2020, p. 121-125
Pages: 121-125
Journal: Medical Journal of Australia
Abstract: Objective: To investigate the incidence of second primary cancers in people diagnosed with cancer during childhood. Design, setting: Retrospective, population-based study; analysis of Australian Childhood Cancer Registry data. Participants: People alive at least two months after being diagnosed before the age of 15 years with a primary cancer, 1983–2013, followed until 31 December 2015 (2–33 years' follow-up). Main outcome measures: Risks of second primary cancer compared with the general population, expressed as standardised incidence ratios (SIRs). Results: Among 18 230 people diagnosed with cancer during childhood, 388 (2%) were later diagnosed with second primary cancers; the estimated 30-year cumulative incidence of second cancers was 4.4% (95% CI, 3.8–5.0%). The risk of a new primary cancer was five times as high as for the general population (SIR, 5.13; 95% CI, 4.65–5.67). Relative risk of a second primary cancer was greatest for people who had childhood rhabdomyosarcoma (SIR, 19.9; 95% CI, 14.4–27.6). Relative risk was particularly high for children who had undergone both chemotherapy and radiotherapy (SIR, 9.80; 95% CI, 8.35–11.5). Relative risk peaked during the 5 years following the first diagnosis (2 to less than 5 years: SIR, 10.3; 95% CI, 8.20–13.0), but was still significant at 20–33 years (SIR, 2.58; 95% CI, 2.02–3.30). The most frequent second primary cancers were thyroid carcinomas (65 of 388, 17%) and acute myeloid leukaemias (57, 15%). Conclusions: Survivors of childhood cancer remain at increased risk of a second primary cancer well into adulthood. As the late effects of cancer treatment probably contribute to this risk, treatments need to be refined and their toxicity reduced, without reducing their benefit for survival.L20036391192019-11-28
DOI: 10.5694/mja2.50425
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L2003639119&from=exporthttp://dx.doi.org/10.5694/mja2.50425 |
Keywords: rhabdomyosarcoma;retrospective study;antineoplastic agentacute myeloid leukemia;adolescent;adult;adulthood;article;Australia;cancer chemotherapy;cancer incidence;cancer radiotherapy;cancer registry;cancer risk;cancer survival;cancer survivor;cancer therapy;child;childhood cancer;controlled study;female;follow up;human;infant;risk benefit analysis;school child;second cancer;standardized incidence ratio;thyroid carcinoma;male;primary tumor;preschool child;population research;major clinical study;risk assessment
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

62
checked on Mar 27, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.